{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:38:57Z","timestamp":1765057137145,"version":"3.46.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The role of minimal residual disease (MRD) testing is well defined in curable hematological malignancies like acute lymphoblastic leukemia. However, in chronic lymphocytic leukemia (CLL), which is an incurable low-grade lymphoma, MRD is mostly investigational, especially in the relapsed setting. Newer techniques are trying to get to even deeper levels than before\u2014for instance, 10\u22126 with sequencing. Here we describe the current techniques of MRD testing in CLL and explore the applications of these modalities in relapsed\/refractory CLL in novel targeted therapies, cellular therapy, and other immunotherapies that can lead to deep and durable remissions, especially when used in combinations. More and more prospective interventional trials are now using MRD testing to inform decisions, and the data from these trials will further elucidate the best use of MRD testing in CLL patients. For now, MRD testing is not used for treatment decisions in the real world, although it can be done for monitoring in patients with high-risk genetics.<\/jats:p>","DOI":"10.1182\/hematology.2025000685","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:08:46Z","timestamp":1764943726000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["The role of MRD monitoring and options for CLL management in relapsed\/refractory disease"],"prefix":"10.1182","volume":"2025","author":[{"given":"Brian","family":"Sworder","sequence":"first","affiliation":[{"name":"Department of Hematology\u200a\/\u200aHematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"Department of Hematology\u200a\/\u200aHematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"11","key":"2025120616334918300_hem2025000685C1","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2025120616334918300_hem2025000685C2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"2025120616334918300_hem2025000685C3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cyto.b.21067","article-title":"A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia","volume":"84B(2)","author":"Sartor","year":"2013","journal-title":"Cytom B Clin"},{"issue":"12","key":"2025120616334918300_hem2025000685C4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"28","key":"2025120616334918300_hem2025000685C5","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025120616334918300_hem2025000685C6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2025120616334918300_hem2025000685C7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","article-title":"Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment","volume":"30","author":"Widman","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"2025120616334918300_hem2025000685C8","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025120616334918300_hem2025000685C9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2025120616334918300_hem2025000685C10","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2025120616334918300_hem2025000685C11","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616334918300_hem2025000685C12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med."},{"issue":"6","key":"2025120616334918300_hem2025000685C13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Furstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"2025120616334918300_hem2025000685C14","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2025120616334918300_hem2025000685C15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"2025120616334918300_hem2025000685C16","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","article-title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"61","author":"Fraser","year":"2020","journal-title":"Leuk amp; Lymphoma"},{"issue":"15","key":"2025120616334918300_hem2025000685C17","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/bloodadvances.2024015180","article-title":"Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION\/HO141 trial","volume":"9","author":"Niemann","year":"2025","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2025120616334918300_hem2025000685C18","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2021-154203","article-title":"Fixed duration combination therapy with ibrutinib (ibr) and venetoclax (ven) leads to deep responses in relapsed\/refractory (rel\/ref) chronic lymphocytic leukemia (CLL): results of a phase 2 study","volume":"138","author":"Siddiqi","year":"2021","journal-title":"Blood"},{"issue":"10402","key":"2025120616334918300_hem2025000685C19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2025120616334918300_hem2025000685C20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","article-title":"Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (r\/r) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1\/2 transcend CLL 004 Study","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025120616334918300_hem2025000685C21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"issue":"30","key":"2025120616334918300_hem2025000685C22","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: The CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol."},{"issue":"8","key":"2025120616334918300_hem2025000685C23","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/39\/2470061\/39sworder.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/39\/2470061\/39sworder.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:33:56Z","timestamp":1765056836000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/39\/556909\/The-role-of-MRD-monitoring-and-options-for-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000685","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"type":"print","value":"1520-4391"},{"type":"electronic","value":"1520-4383"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}